Abstract
The concept that the gut microbiota plays a major role in the development of pouchitis in ulcerative colitis patients after restorative proctocolectomy with ileal pouch-anal anastomosis, is widely accepted and supported by a widespread use of some antibiotics (metronidazole and/or ciprofloxacin, rifaximin) to treat this condition.
A possible, safer therapeutic alternative is represented by probiotics. To date the controlled studies addressing the possible efficacy of probiotic agents in the treatment of active pouchitis are few and inconclusive. By contrast the prophylactic use of a probiotic mixture (VSL #3) appears to be able to prevent development of pouchitis. The most convincing results have been observed in the maintenance of remission, where the probiotic mixture has been found, in most of the performed controlled trials, significantly effective in preventing pouchitis recurrence.
Keywords: Pouchitis, gut microbiota, antibiotics, probiotics.
Current Pharmaceutical Design
Title:Role of Probiotics in the Management of Pouchitis
Volume: 20 Issue: 28
Author(s): Mario Guslandi
Affiliation:
Keywords: Pouchitis, gut microbiota, antibiotics, probiotics.
Abstract: The concept that the gut microbiota plays a major role in the development of pouchitis in ulcerative colitis patients after restorative proctocolectomy with ileal pouch-anal anastomosis, is widely accepted and supported by a widespread use of some antibiotics (metronidazole and/or ciprofloxacin, rifaximin) to treat this condition.
A possible, safer therapeutic alternative is represented by probiotics. To date the controlled studies addressing the possible efficacy of probiotic agents in the treatment of active pouchitis are few and inconclusive. By contrast the prophylactic use of a probiotic mixture (VSL #3) appears to be able to prevent development of pouchitis. The most convincing results have been observed in the maintenance of remission, where the probiotic mixture has been found, in most of the performed controlled trials, significantly effective in preventing pouchitis recurrence.
Export Options
About this article
Cite this article as:
Guslandi Mario, Role of Probiotics in the Management of Pouchitis, Current Pharmaceutical Design 2014; 20 (28) . https://dx.doi.org/10.2174/13816128113196660724
DOI https://dx.doi.org/10.2174/13816128113196660724 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Rodent Models of Persistent Pain in Drug Discovery and Development
Current Pharmaceutical Biotechnology Etravirine in the Treatment of HIV-1: A Clinical Overview for Healthcare Professionals
Current HIV Research Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells
Current Cancer Drug Targets Deciphering G Protein-Coupled Receptor Biology with Fluorescence-based Methods
Current Pharmaceutical Biotechnology Use of a Weighted, Automated Analysis of the Differential Blood Count to Differentiate Sepsis from Non-Infectious Systemic Inflammation: The Intensive Care Infection Score (ICIS)
Inflammation & Allergy - Drug Targets (Discontinued) Retrovirus Silencing and Vector Design: Relevance to Normal and Cancer Stem Cells?
Current Gene Therapy Acute Passivation of Vulnerable Plaques with Wild-Type Apolipoprotein A-I in ApoE-Deficient Mice
Vascular Disease Prevention (Discontinued) Patent Annotations
Recent Patents on Anti-Infective Drug Discovery Gut Microbiota Modulation and Mucosal Immunity: Focus on Rifaximin
Mini-Reviews in Medicinal Chemistry Intracellular and Extracellular Zinc Detection by Organic Fluorescent Receptor
Current Organic Chemistry Is there a Teratogenicity Risk Associated with Cannabis and Synthetic Cannabimimetics’ (‘Spice’) Intake?
CNS & Neurological Disorders - Drug Targets Amyloid-Beta Peptide 1-42 Causes Microtubule Deregulation through N-methyl-D-aspartate Receptors in Mature Hippocampal Cultures
Current Alzheimer Research Efficient <i>In Vitro</i> Refolding and Characterization of Major Histocompatibility Complex Class I-Related Chain Molecules A (MICA) and Natural Killer Group 2 Member D (NKG2D) Expressed in <i>E. coli</i>
Protein & Peptide Letters Histological and Direct Evidence for the Role of Complement in the Neuroinflammation of AD
Current Alzheimer Research Molecular Docking Simulations as a Prominent Tool to Envisage the Preformulation Perspectives of Oral Hypoglycaemic Agents with β-cyclodextrin
Letters in Drug Design & Discovery Subject Index to Volume 5
Current Protein & Peptide Science Time Trends and Gender Differences in Incidence and Prevalence of Type 1 Diabetes in Sweden
Current Diabetes Reviews Preface [Hot Topic: Reactive Oxygen and Nitrogen Species in the Context of Autoimmune Responses (Executive Editors: D. Stahl and W. Sibrowski)]
Current Pharmaceutical Design The Potential of Selected Prostanoid Receptors as Targets in a New Therapeutic Strategy for Allergy and Immune Diseases
Current Drug Safety Unfolding the Pathophysiological Role of Bioactive Lysophospholipids
Current Drug Targets - Immune, Endocrine & Metabolic Disorders